Targeting sphingosine-1-phosphate (S1P)/sphingosine-1-phosphate receptor 1 (S1PR1) using a clinically relevant and available drug or other approaches is potentially an effective, new therapeutic modality for treating the activated B cell-like subtype of diffuse large B-cell lymphoma, a subset of lymphoma that is less responsive to current available therapies. This evidence concerns the gene S1PR1 and lymphoma.